Pictet Asset Management Holding SA Raises Holdings in Cencora, Inc. (NYSE:COR)

Pictet Asset Management Holding SA boosted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 26.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,017 shares of the company's stock after acquiring an additional 26,051 shares during the period. Pictet Asset Management Holding SA owned 0.07% of Cencora worth $28,314,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Whittier Trust Co. boosted its stake in shares of Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC raised its holdings in Cencora by 0.9% in the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after purchasing an additional 46 shares during the period. WASHINGTON TRUST Co lifted its position in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. JFS Wealth Advisors LLC grew its holdings in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. increased its position in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after buying an additional 47 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on COR shares. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company upped their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Finally, Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. The trade was a 21.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 over the last 90 days. Company insiders own 10.80% of the company's stock.

Cencora Trading Down 3.5 %

COR traded down $10.07 on Friday, hitting $279.29. The company had a trading volume of 4,404,535 shares, compared to its average volume of 1,469,415. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business's fifty day simple moving average is $257.28 and its 200 day simple moving average is $242.65. The company has a market cap of $54.16 billion, a PE ratio of 39.73, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.